Melatonina
Anno: 1998
-
Riferimento:Menopause. 1998 Spring;5(1):60-4. Review.Azione della melatonina:Melatonin might be implicated in menopause-associated processes such as breast cancer.Target:Melatonin replacement therapy.
-
Riferimento:Br J Cancer. 1998 Jun;77(12):2129-37.Azione della melatonina:Melatonin (10(-9) M)and atRA (10(-9) M) should be considered for preclinical and clinical evaluation against ER-positive human breast cancer.Target:Oestrogen receptor (ER), all-trans retinoic acid (atRA).
-
Riferimento:Int J Biol Markers. 1998 Jul-Sep;13(3):154-7.Azione della melatonina:Studies evaluating circadian DHEAS secretion in relation in that of the pineal hormone MLT.Target:Dehydroepiandrosteronesulfate (DHEAS).
Anno: 1999
-
Riferimento:BMJ. 1999 Jan 23;318(7178):224-8.Azione della melatonina:Di Bella multitherapy did not show sufficient efficacy in patients with advanced cancer to warrant further clinical testing.Target:386 patients with advanced cancer were enrolled.
-
Riferimento:Oncology. 1999;56(2):169-76.Azione della melatonina:Human breast cancer patients showed a decline in circulating melatonin levels.Target:Tryptophan 2,3-dioxygenase (TDO).
-
Riferimento:Neuro Endocrinol Lett. 1999;20(3-4):139-144.Azione della melatonina:Possible therapeutic significance of melatonin in neoplastic disease.Target:Alterations in melatonin concentrations
-
Riferimento:BMJ. 1999 Jan 23;318(7178):224-8.Azione della melatonina:Di Bella multitherapy did not show sufficient efficacy in patients with advanced cancer to warrant further clinical testing.Target:Di Bella multitherapy.
-
Riferimento:Eur J Cancer. 1999 Nov;35(12):1688-92.Azione della melatonina:MLT (20 mg/day orally) may enhance the efficacy of chemotherapy and reduce its toxicity. Tumour response rate: 42/124 CT + MLT versus 19/126 CT (5-FU plus folinic acid) only.Target:Counteract chemotherapy toxicity.
-
Riferimento:Adv Exp Med Biol. 1999;467:217-26. Review.Azione della melatonina:Effect of MLT in combination with IL-2 or other cytokines in cancer patients and viral diseases including HIV-infected patients.Target:Interleukin-2 (IL-2).
-
Riferimento:Neuro Oncol. 1999 Jul;1(3):212-20.Azione della melatonina:Reasonable support for a causal role of EMF on brain cancer.Target:General review.